GeneFerm Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 08, 2022
Share
GeneFerm Biotechnology Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 166.14 million compared to TWD 133.91 million a year ago. Net income was TWD 25.47 million compared to TWD 18.22 million a year ago. Basic earnings per share from continuing operations was TWD 0.61 compared to TWD 0.45 a year ago. Diluted earnings per share from continuing operations was TWD 0.61 compared to TWD 0.4 a year ago.
For the nine months, sales was TWD 463.77 million compared to TWD 368.73 million a year ago. Net income was TWD 76 million compared to TWD 39.95 million a year ago. Basic earnings per share from continuing operations was TWD 1.84 compared to TWD 1.02 a year ago. Diluted earnings per share from continuing operations was TWD 1.78 compared to TWD 0.93 a year ago.
GeneFerm Biotechnology Co., Ltd. is a Taiwan-based company mainly engaged in the manufacture and sales of health food. Its health food products include fermented products, medicinal mushrooms, lactic acid bacteria products, fruit and vegetable fermented concentrate products, among others. The Company also provides related manufacturing services, as well as health food design, research and development services.